Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Eris Lifesciences Limited (NSE: ERIS), ISIN INE406M01024 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
ERIS last traded at ₹1264.10 (+2.43%), with a 52-week range of ₹1069.00 to ₹1740.00 (as of 6 Nov 2026).
Shareholding as of Sep 2026: promoters 54.74%, FIIs 5.74%, DIIs 20.19%, mutual funds 17.98%.
EquiSense Score (ECS): 67/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.